Tisdag 6 Maj | 13:21:29 Europe / Stockholm

Kalender

Est. tid*
2026-04-24 07:00 Kvartalsrapport 2026-Q1
2026-01-29 N/A Bokslutskommuniké 2025
2025-10-24 07:00 Kvartalsrapport 2025-Q3
2025-07-18 07:00 Kvartalsrapport 2025-Q2
2025-04-29 - Kvartalsrapport 2025-Q1
2025-03-11 - X-dag ordinarie utdelning NOVN 3.50 CHF
2025-03-07 - Årsstämma
2025-01-31 - Bokslutskommuniké 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-23 - Kvartalsrapport 2024-Q1
2024-03-07 - X-dag ordinarie utdelning NOVN 3.30 CHF
2024-03-05 - Årsstämma
2024-01-31 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-09-15 - Extra Bolagsstämma
2023-07-18 - Kvartalsrapport 2023-Q2
2023-05-07 - Årsstämma
2023-04-25 - Kvartalsrapport 2023-Q1
2023-03-09 - X-dag ordinarie utdelning NOVN 3.20 CHF
2023-03-07 - Årsstämma
2023-02-01 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-07-19 - Kvartalsrapport 2022-Q2
2022-04-26 - Kvartalsrapport 2022-Q1
2022-03-08 - X-dag ordinarie utdelning NOVN 3.10 CHF
2022-03-04 - Årsstämma
2022-02-02 - Bokslutskommuniké 2021
2021-10-26 - Kvartalsrapport 2021-Q3
2021-07-21 - Kvartalsrapport 2021-Q2
2021-04-27 - Kvartalsrapport 2021-Q1
2021-03-04 - X-dag ordinarie utdelning NOVN 3.00 CHF
2021-03-02 - Årsstämma
2021-01-26 - Bokslutskommuniké 2020
2020-10-27 - Kvartalsrapport 2020-Q3
2020-07-21 - Kvartalsrapport 2020-Q2
2020-04-28 - Kvartalsrapport 2020-Q1
2020-03-03 - X-dag ordinarie utdelning NOVN 2.95 CHF
2020-02-28 - Årsstämma
2020-01-29 - Bokslutskommuniké 2019
2019-10-22 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-04-24 - Kvartalsrapport 2019-Q1
2025-01-13 07:15:00

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent.

We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.

There are currently no generic versions of Entresto available in the US.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com 
 
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com